ArticleVirulence
Coming of AGE: facile generation of attenuated vaccine strains through heterologous gene expression.
Article in Virulence. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Live attenuated vaccine strains for bacterial pathogens are conventionally constructed by inactivating genes important for virulence or metabolism to render the organism less virulent. Ideally, these strains follow a natural route of infection, yet elicit an immune response without causing disease. In particular, live attenuated vaccines often have the advantage of generating cellular immune responses that killed organisms and purified antigens fail to stimulate. Importantly, a fine balance between attenuation and sufficient persistence in the host must be achieved in order to produce a protective and durable immune response. Unfortunately, the reality is that, in most cases, the complete repertoire of factors responsible for virulence is unknown or not well understood, hindering the creation of attenuated vaccine strains. Thus, the generation of live attenuated vaccines would be greatly facilitated by novel, portable approaches for attenuating Gram-negative pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.